Ezzat Elhassadi, MD

home / authors / ezzat-elhassadi-md

Articles

Dr. Elhassadi on the Subtypes of MCL

Dr. Elhassadi on the Subtypes of MCL

Ezzat Elhassadi, MD
July 10th 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses the subtypes of mantle cell lymphoma (MCL).

Read More

Dr. Elhassadi on the Relationship Between p53 Expression and Prognosis in MCL

Dr. Elhassadi on the Relationship Between p53 Expression and Prognosis in MCL

Ezzat Elhassadi, MD
June 28th 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses p53 expression and prognosis in mantle cell lymphoma (MCL).

Read More

Dr. Elhassadi on 10-Year Single-Center Experience With TP53 Status in MCL

Dr. Elhassadi on 10-Year Single-Center Experience With TP53 Status in MCL

Ezzat Elhassadi, MD
June 22nd 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).

Read More

Dr. Elhassadi Discusses the Outlook of Patients With p53-Mutated MCL

Dr. Elhassadi Discusses the Outlook of Patients With p53-Mutated MCL

Ezzat Elhassadi, MD
June 19th 2019

Ezzat Elhassadi, MD, consultant hematologist, Haematology Services, University Hospital Waterford, discusses the outlook of patients with p53-mutated mantle cell lymphoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need